avantiavanti schreef op 13 maart 2016 11:17:
Als ik de de hoeveelheid shortly's en soons zie in onderstaand abstract van de presentatie, dan valt er binnenkort weer genoeg on topic gedachtes, meningen etc. uit te wisselen.
Maar laten we nou niet te ingewikkeld en chagrijnig doen over posts die niet direct ter zake doen. Inmiddels vult die discussie het forum echt tot vervelends toe vind ik.
Dus Tonneke, fijn dat je vandaag op 23 fijne jaren met je vrouw mag terugkijken!
Quote van Onno van vrijdag 4 maart: "Looking forward to the discussions with EMA and FDA regarding the end of Phase 2 meetings and the planning of the Phase 2, regarding not only RA but also Crohn's. The meetings on RA have been scheduled and
will be happening relatively soon, but also Crohn's is anticipated
very shortly,
soon after we have released the 20 week data, so that we can start the Phase 3 for close also in 2016."
And then a question we've received a lot since AbbVie decided not to in-license filgotinib. How our relation is with regard to cystic fibrosis and I
can tell you and assure you that, that relation is sound and good. We have been renegotiating the CF alliance because the alliance has become
much bigger or the program has become much bigger than what we had anticipated. When we signed contract a couple of years back, at that time we were only thinking about the dual for the Class II mutations, where as we now talking about a triple combo therapy, which means that, a number of the terms had to be re-discussed with AbbVie and we hope to announce an expanded alliance around CF
shortly with them.
If we go to the news flow regarding our pipeline, you see that we have
a lot of data coming up in the first half as well as in the second half. I've
talked extensively already about RA and Crohn's for filgotinib. With CF, we anticipate the results of our first corrector 2222 in the first half. In the
second half, we expect the potentiator 1837 in the Class III mutation, as well as our C2 corrector that will go into Phase 1 and the result should be there as well before the end of the year.